Systematic review of pharmacoeconomic models for schizophrenia

References

• Jin H, Mosweu I. The societal cost of schizophrenia: A systematic review. Pharmacoeconomics. 2017;35:1–10.
   Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. The Lancet. 2012;380:2163–2196.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative effi cacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry. 1990;41:850–854.
   PubMedGoogle Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11:95–106.
   PubMedGoogle Scholar
• Kruse G, Wong BJO, Duh MS, et al. Systematic literature review of the methods used to compare newer second-generation agents for the management of schizophrenia: A focus on health technology assessment. Pharmacoeconomics. 2015;33:1049–1067.
   PubMed Web of Science ®Google Scholar
• Scheele B, Mauskopf J, Brodtkorb T-H, et al. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014;14:235–257.
   Web of Science ®Google Scholar
• Németh B, Fasseeh A, Molnár A, et al. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2018; 18(3): 267–275.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Psychosis and schizophrenia: management. NICE Guideline CG82; 2009; Available from: https://www.nice.org.uk/guidance/cg82. Last accessed 2018 Apr 04
   Google Scholar
• National Institute for Health and Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. NICE Guideline CG178; 2014; Available from: https://www.nice.org.uk/guidance/cg178. Last accessed 2018 Apr 04
   Google Scholar
• National Institute for Health and Clinical Excellence. Aripiprazole for schizophrenia in people aged 15 to 17 years. NICE Technology apprasial guidance TA213; 2011; Available from: www.nice.org.uk/guidance/TA213. Last accessed 2018 Apr 04
   Google Scholar
• Kobelt G. Health economics: an introduction to economic evaluation. London: Office of Health Economiics; 2013.
   Google Scholar
• Heeg BMS, Damen J, Buskens E, et al. Modelling approaches: the case of schizophrenia. Pharmacoeconomics. 2008;26:633–648.
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force–2. Value Health. 2012;15:804–811.
   PubMed Web of Science ®Google Scholar
• Alexeyeva I, Mauskopf J, Earnshaw SR, et al. Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling. J Med Econ. 2008;4:179–192.
   Google Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7:1–193.
   PubMedGoogle Scholar
• Bernardo M, Azanza JR, Rubio-Terres C, et al. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Actas Esp Psiquiatr. 2007;35:259–262.
   Web of Science ®Google Scholar
• Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract. 2007;13:453–460.
   PubMed Web of Science ®Google Scholar
• Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the USA. J Med Econ. 2014;17:567–576.
   PubMedGoogle Scholar
• Colombo GL, Caruggi M, Di Matteo S, et al. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat. 2008;4:967–976.
   PubMedGoogle Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(Suppl 1):35–47.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23(Suppl 1):75–89.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin. 2008;24:3341–3355.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Muser E, Doshi D, et al. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. J Med Econ. 2012;15:623–634.
   PubMedGoogle Scholar
• Einarson TR, Pudas H, Zilbershtein R, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ. 2013;16:1096–1105.
   PubMedGoogle Scholar
• Einarson TR, Zilbershtein R, Skoupa J, et al. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ. 2013;16:1089–1095.
   PubMedGoogle Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr. 2013;25:85–94.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11:18.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014;68:416–427.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Goswami P, et al. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ. 2016;19:111–120.
   PubMed Web of Science ®Google Scholar
• Ganguly R, Miller LS, Martin BC. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res. 2003;63:111–119.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz AJ, Perez-Costillas L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2:8.
   PubMedGoogle Scholar
• Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry. 2008;7:16.
   PubMedGoogle Scholar
• Graham CN, Mauskopf JA, Lawson AH, et al. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012;15:55–64.
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess. 2005;9:iii–iv. 1–156.
   Web of Science ®Google Scholar
• Jukic V, Jakovljevic M, Filipcic I, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in croatia. Value in Health Regional Issues. 2013;2:181–188.
   PubMedGoogle Scholar
• Kongsakon R, Leelahanaj T, Price N, et al. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. J Med Assoc Thai. 2005;88:1267–1277.
   PubMedGoogle Scholar
• Layton S, Barbeau M. Generic replacement of clozapine: a simple decision model from a Canadian perspective. Curr Med Res Opin. 2004;20:453–459.
   PubMed Web of Science ®Google Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61:1979–1988.
   PubMed Web of Science ®Google Scholar
• Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol. 2001;8:199–206.
   PubMedGoogle Scholar
• Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4:137–156.
   Google Scholar
• Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59:385–394.
   PubMed Web of Science ®Google Scholar
• Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009;12(Suppl 3):S66–9.
   PubMed Web of Science ®Google Scholar
• Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol. Pharmacoeconomics. 2000;17:383–389.
   Google Scholar
• Anh NQ, Linh BN, Ha NT, et al. Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study. Glob Public Health. 2015;10(Supppl 1):S21–39.
   Google Scholar
• Beard SM, Maciver F, Clouth J, et al. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. Eur J Health Econ. 2006;7:165–172.
   PubMedGoogle Scholar
• Bobes J, Canas F, Rejas J, et al. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1287–1297.
   PubMed Web of Science ®Google Scholar
• Davies A, Vardeva K, Loze JY, et al. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24:3275–3285.
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics. 2016;34:363–391.
   PubMed Web of Science ®Google Scholar
• Emsley R, Booysen F. Cost-effectiveness of an atypical conventional antipsychotic in South Africa: an economic evaluation of quetiapine versus haloperidol in the treatment of patients partially responsive to previous antipsychotics. South Afr J Psychiatry. 2004;10:7.
   Google Scholar
• Frey S, Linder R, Juckel G, et al. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a markov model parameterized using administrative data. Eur J Health Econ. 2014;15:133–142.
   Web of Science ®Google Scholar
• Hansen K, Francois C, Toumi M, et al. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. Eur J Health Econ. 2002;3:173–179.
   PubMedGoogle Scholar
• Kasteng F, Eriksson J, Sennfalt K, et al. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124:214–225.
   PubMed Web of Science ®Google Scholar
• Kim B-R-M, Lee T-J, Lee H-J, et al. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea. Value in Health Regional Issues. 2012;1:59–65.
   Google Scholar
• Lachaine J, Beauchemin C, Mathurin K, et al. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. J Med Econ. 2014;17:296–304.
   PubMedGoogle Scholar
• Lecomte P, De Hert M, Van Dijk M, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health. 2000;3:1–11.
   PubMedGoogle Scholar
• Lin L, Zhao YJ, Zhou HJ, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31:84–92.
   PubMed Web of Science ®Google Scholar
• Lindner LM, Marasciulo AC, Farias MR, et al. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian healthcare system. Rev Saude Publica. 2009;43(Suppl 1):62–69.
   PubMedGoogle Scholar
• Lindstrom E, Eberhard J, Fors BM, et al. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry. 2011;65:403–413.
   PubMed Web of Science ®Google Scholar
• Lubinga SJ, Mutamba BB, Nganizi A, et al. A cost-effectiveness analysis of antipsychotics for treatment of schizophrenia in Uganda. Appl Health Econ Health Policy. 2015;13:493–506.
   PubMed Web of Science ®Google Scholar
• Magnus A, Carr V, Mihalopoulos C, et al. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry. 2005;39:44–54.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010;16:744–755.
   PubMed Web of Science ®Google Scholar
• Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15:844–861.
   PubMedGoogle Scholar
• Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res. 2003;31:188–196.
   PubMed Web of Science ®Google Scholar
• O’Day K, Rajagopalan K, Meyer K, et al. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459–470.
   PubMedGoogle Scholar
• Palmer CS, Brunner E, Ruiz-Flores LG, et al. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Res. 2002;33:572–580.
   PubMed Web of Science ®Google Scholar
• Park T, Kuntz KM. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. Value Health. 2014;17:310–319.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25:427–434.
   PubMed Web of Science ®Google Scholar
• Phanthunane P, Vos T, Whiteford H, et al. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc. 2011;9:6.
   PubMedGoogle Scholar
• Rajagopalan K, Hassan M, O’Day K, et al. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. J Med Econ. 2013;16:951–961.
   Google Scholar
• Tilden D, Aristides M, Meddis D, et al. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther. 2002;24:1648–1667.
   PubMed Web of Science ®Google Scholar
• Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model. J Ment Health Policy Econ. 2004;7:77–85.
   PubMedGoogle Scholar
• Zeidler J, Mahlich J, Greiner W, et al. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11:509–521.
   PubMedGoogle Scholar
• Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the USA. J Med Econ. 2012;15:531–547.
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the USA. Cost Eff Resour Alloc. 2009;7:4.
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the USA: a micro-simulation economic decision model. Curr Med Res Opin. 2011;27:713–730.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a markov model. Value Health. 2004;7:569–584.
   PubMed Web of Science ®Google Scholar
• Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics. 2005;23(Suppl 1):62–74.
   Google Scholar
• Damen J, Thuresson PO, Heeg B, et al. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy. 2008;6:189–197.
   PubMedGoogle Scholar
• Dilla T, Moller J, O’Donohoe P, et al. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. BMC Psychiatry. 2014;14:298.
   PubMed Web of Science ®Google Scholar
• Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics. 2005;23(Suppl 1):17–33.
   PubMed Web of Science ®Google Scholar
• Heeg B, Buskens E, Botteman M, et al. The cost-effectiveness of atypicals in the UK. Value Health. 2008;11:1007–1021.
   PubMed Web of Science ®Google Scholar
• Heeg BM, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin. 2008;24:349–358.
   PubMed Web of Science ®Google Scholar
• Hensen M, Heeg B, Lothgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8:327–341.
   PubMedGoogle Scholar
• Laux G, Heeg B, Van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23(Suppl 1):49–61.
   PubMed Web of Science ®Google Scholar
• Treur M, Heeg B, Moller HJ, et al. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res. 2009;9:32.
   PubMed Web of Science ®Google Scholar
• Treur M, Baca E, Bobes J, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ. 2012;15(Suppl 1):26–34.
   Google Scholar
• Chisholm D. Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization. World Psychiatry. 2005;4:37–44.
   PubMedGoogle Scholar
• Chisholm D, Gureje O, Saldivia S, et al. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ. 2008;86:542–551.
   PubMed Web of Science ®Google Scholar
• Chisholm D, Saxena S. Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e609.
   Web of Science ®Google Scholar
• Strand KB, Chisholm D, Fekadu A, et al. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health Policy Plan. 2016;31:504–513.
   PubMed Web of Science ®Google Scholar